Please see full Prescribing Information, including Boxed Warning. Learn about Lo Loestrin® Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets). A combination oral contraceptive with the lowest daily dose of estrogen with just 10 mcg.


With 20 mcg of ethinyl estradiol in a 24/4 regimen, Taytulla provides pregnancy prevention with short, light periods.1,2,*

Effective contraception with an established bleeding profile1,2

Established 24/4 regimen provides short, light periods1,2

  • In a pivotal clinical trial, patient-reported intensity of withdrawal bleeding was lighter than normal2
  • The mean duration of withdrawal bleeding in women taking Taytulla was 2.42 days between Cycle 2 and Cycle 6.2
    In a retrospective clinical study of women not taking oral contraceptives, the average duration of withdrawal bleeding was 5.2 days3
  • The Pearl Index was 1.82 (95% CI: 0.59-4.25)1
  • 20 mcg of ethinyl estradiol in a 24/4 regimen1

Learn more about the bleeding profile of Taytulla

* Each subject recorded presence and intensity of bleeding daily in a diary using the terms "none," "light," "normal," and heavy."2


Taytulla is an estrogen/progestin combination oral contraceptive (COC) indicated for use by females of reproductive age to prevent pregnancy. Efficacy in women with a body mass index (BMI) of more than 35 kg/m2 has not been evaluated.


Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke.


Taytulla is contraindicated in pregnant patients, in women with a high risk of arterial or venous thrombotic diseases, liver tumors (benign or malignant) or liver disease, undiagnosed abnormal uterine bleeding, or breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past, and in women using Hepatitis C drugs containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.

Warnings and Precautions

Discontinue Taytulla if a thrombotic event occurs, and at least 4 weeks before and through 2 weeks after major surgery. Taytulla should not be started any earlier than 4 weeks after delivery, in women who are not breastfeeding. If jaundice occurs, treatment should be discontinued.

Taytulla should not be prescribed for women with uncontrolled hypertension or hypertension with vascular disease. Women who are prediabetic or diabetic should be monitored while using Taytulla. Alternate contraceptive methods should be considered for women with uncontrolled dyslipidemia. Patients using Taytulla who have a significant change in headaches or irregular bleeding or amenorrhea should be evaluated.

Adverse Reactions

In the clinical trial for Taytulla, the most common adverse reactions (incidence ≥2%) were headache, vaginal candidiasis, nausea, menstrual cramps, breast tenderness, bacterial vaginitis, abnormal cervical smear, acne, mood swings, and weight gain.

Patients should be counseled that COCs do not protect against HIV infection (AIDS) and other sexually transmitted diseases.

Please see full Prescribing Information, including Boxed Warning, for Taytulla.


  1. Taytulla prescribing information. Irvine, CA: Allergan USA, Inc; 2017.
  2. Data on file. Allergan USA, Inc.
  3. Creinin MD, Keverline S, Meyn LA. How regular is regular? An analysis of menstrual cycle regularity. Contraception. 2004;70(4):289-292.
  4. Aylwin EA, Banbury S, Ferdinando JJC, de Nijs H, inventors; RP Scherer Technologies Inc, assignee. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic [sic] surfactants. US patent 6,652,880. November 25, 2003.